Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817804 | 1.00 | LMNA (0.58) | LMNACYP1A2THRBBLMCREBBP | |
| Trimelamol SCHEMBL1419460 | 0.92 | LMNA (0.42) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL3115681 | 0.91 | LMNA (0.48) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL27649444 | 0.89 | LMNA (0.46) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL12610491 | 0.82 | LMNA (0.35) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL13562967 | 0.82 | LMNA (0.35) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL11764977 | 0.80 | LMNA (0.52) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL11772001 | 0.80 | LMNA (0.52) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL22058984 | 0.79 | LMNA (0.58) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL19272104 | 0.79 | LMNA (0.58) | LMNACYP1A2THRBBLMCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237561-B1 | USE OF A CHEMICAL MECHANICAL POLISHING (CMP) COMPOSITION FOR POLISHING OF COBALT AND / OR COBALT ALLOY COMPRISING SUBSTRATES | BASF SE (DE) | 2019-01-23 | — | — | EP | claimed |
| CN-109745316-B | Combination therapy for the treatment of cancer | EPIZYME股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-11274301-B2 | Micro-RNA inhibitors and their uses in disease | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2022-03-15 | — | — | US | disclosed |
| US-10131905-B2 | Micro-RNA inhibitors and their uses in disease | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180105813-A1 | Treatment of Cancers with Micro-RNA Inhibitors | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180073025-A1 | Micro-RNA Inhibitors and Their Uses in Disease | BETH ISRAEL DEACONESS MEDICAL CENTER | 2018-03-15 | — | — | US | disclosed |
| EP-3159410-A2 | MICRO-RNA INHIBITORS AND THEIR USES IN DISEASE | Beth Israel Deaconess Medical Center, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20160292381-A1 | METHODS OF SIMULATING CHEMOTHERAPY FOR A PATIENT | HELOMICS CORP (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2364302-B1 | TRIAZINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIV BASEL (CH) | 2016-10-05 | — | — | EP | disclosed |
| EP-2504320-B1 | Melamine based mannich-compounds and a process for obtaining the same | BOREALIS AGROLINZ MELAMINE (AT) | 2015-10-14 | — | — | EP | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-20090104647-A1 | METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT | CYTOMICS, INC. | 2009-04-23 | — | — | US | disclosed |
| EP-1020462-B1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2004-02-11 | — | — | EP | disclosed |
| US-6251900-B1 | Heterocyclic compounds and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1020462-A1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0629622-B1 | S-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5489591-A | INHIBITORS OF AROMATASE; TREATING ENDOMETRIOSIS, BREAST CANCER CYSTIC OVARIES | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-02-06 | — | — | US | disclosed |
| EP-0629622-A1 | s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1994-12-21 | — | — | EP | disclosed |
| WO-1992016513-A1 | NEW COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITA (GB) | 1992-10-01 | — | — | WO | disclosed |
| EP-0505220-A1 | New compounds for use in the treatment of cancer | JARMAN, Michael (GB) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131905-B2 | Micro-RNA inhibitors and their uses in disease | TP53, IGF2BP3, TP53BP1 | LMNA 440/4885CYP1A2 4856/4885THRB 1929/4885 |
| US-20180073025-A1 | Micro-RNA Inhibitors and Their Uses in Disease | TP53, IGF2BP3, TP53BP1 | LMNA 440/4885CYP1A2 4856/4885THRB 1929/4885 |
| US-11274301-B2 | Micro-RNA inhibitors and their uses in disease | TP53, IGF2BP3, IGF2BP1 | LMNA 425/4885CYP1A2 4861/4885THRB 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.